Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 109 resultater
Tid
Selskap
Tittel
Sektor
Kategori
20 Nov 2024
07:00 CET
ARGENX SE
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
20103010 Biotechnology
Other subject
11 Nov 2024
13:30 CET
ARGENX SE
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
20103010 Biotechnology
Other subject
05 Nov 2024
07:00 CET
ARGENX SE
argenx to Participate at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
31 Oct 2024
07:00 CET
ARGENX SE
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
20103010 Biotechnology
Other subject
24 Oct 2024
07:00 CEST
ARGENX SE
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
20103010 Biotechnology
Other subject
15 Oct 2024
07:00 CEST
ARGENX SE
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
20103010 Biotechnology
Other subject
19 Sep 2024
07:00 CEST
ARGENX SE
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
20103010 Biotechnology
Other subject
28 Aug 2024
07:00 CEST
ARGENX SE
argenx to Present at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
25 Jul 2024
07:00 CEST
ARGENX SE
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
20103010 Biotechnology
Other subject
18 Jul 2024
07:00 CEST
ARGENX SE
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
20103010 Biotechnology
Other subject
16 Jul 2024
06:30 CEST
ARGENX SE
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
20103010 Biotechnology
Other subject
25 Jun 2024
22:30 CEST
ARGENX SE
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
20103010 Biotechnology
Other subject
21 Jun 2024
22:50 CEST
ARGENX SE
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
20103010 Biotechnology
Other subject
17 Jun 2024
07:00 CEST
ARGENX SE
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
20103010 Biotechnology
Other subject
04 Jun 2024
07:00 CEST
ARGENX SE
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
20103010 Biotechnology
Other subject
09 May 2024
07:00 CEST
ARGENX SE
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
20103010 Biotechnology
Other subject
07 May 2024
23:30 CEST
ARGENX SE
argenx announces results of Annual General Meeting of Shareholders
20103010 Biotechnology
Other subject
07 May 2024
07:00 CEST
ARGENX SE
argenx to Present at BofA Securities 2024 Health Care Conference
20103010 Biotechnology
Other subject
02 May 2024
07:00 CEST
ARGENX SE
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
20103010 Biotechnology
Other subject
16 Apr 2024
07:00 CEST
ARGENX SE
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
20103010 Biotechnology
Other subject
27 Mar 2024
07:00 CET
ARGENX SE
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
20103010 Biotechnology
Other subject
26 Mar 2024
21:00 CET
ARGENX SE
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
20103010 Biotechnology
Other subject
26 Mar 2024
07:00 CET
ARGENX SE
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
20103010 Biotechnology
Other subject
07 Mar 2024
22:01 CET
ARGENX SE
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
20103010 Biotechnology
Other subject
29 Feb 2024
07:00 CET
ARGENX SE
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
20103010 Biotechnology
Other subject
26 Feb 2024
07:00 CET
ARGENX SE
argenx to Present at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
22 Feb 2024
07:00 CET
ARGENX SE
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
20103010 Biotechnology
Other subject
20 Feb 2024
07:00 CET
ARGENX SE
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
20103010 Biotechnology
Other subject
18 Jan 2024
07:00 CET
ARGENX SE
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
20103010 Biotechnology
Other subject
08 Jan 2024
07:00 CET
ARGENX SE
argenx Highlights 2024 Strategic Priorities
20103010 Biotechnology
Other subject
02 Jan 2024
07:00 CET
ARGENX SE
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
20103010 Biotechnology
Other subject
20 Dec 2023
07:00 CET
ARGENX SE
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
20103010 Biotechnology
Other subject
28 Nov 2023
07:00 CET
ARGENX SE
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
20103010 Biotechnology
Other subject
16 Nov 2023
13:40 CET
ARGENX SE
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
20103010 Biotechnology
Other subject
01 Nov 2023
07:00 CET
ARGENX SE
argenx to Present at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
01 Nov 2023
07:00 CET
ARGENX SE
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
20103010 Biotechnology
Other subject
31 Oct 2023
07:00 CET
ARGENX SE
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
20103010 Biotechnology
Other subject
24 Oct 2023
07:00 CEST
ARGENX SE
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
20103010 Biotechnology
Other subject
21 Sep 2023
07:00 CEST
ARGENX SE
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
20103010 Biotechnology
Other subject
15 Sep 2023
07:00 CEST
ARGENX SE
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
20103010 Biotechnology
Other subject
30 Aug 2023
07:00 CEST
ARGENX SE
argenx to Present at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
27 Jul 2023
07:00 CEST
ARGENX SE
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
20103010 Biotechnology
Other subject
24 Jul 2023
22:30 CEST
ARGENX SE
argenx announces closing of global offering
20103010 Biotechnology
Other subject
20 Jul 2023
07:00 CEST
ARGENX SE
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
20103010 Biotechnology
Other subject
19 Jul 2023
23:58 CEST
ARGENX SE
argenx announces full exercise of underwriters’ option to purchase additional ADSs
20103010 Biotechnology
Other subject
19 Jul 2023
03:30 CEST
ARGENX SE
argenx raises $1.1 billion in gross proceeds in a global offering
20103010 Biotechnology
Other subject
17 Jul 2023
22:01 CEST
ARGENX SE
argenx announces launch of proposed global offering
20103010 Biotechnology
Other subject
17 Jul 2023
07:00 CEST
ARGENX SE
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
20103010 Biotechnology
Other subject
30 Jun 2023
15:39 CEST
ARGENX SE
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
20103010 Biotechnology
Other subject
21 Jun 2023
00:12 CEST
ARGENX SE
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva